Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors

Kobayashi,Hiromasa; Hamasaki,Makoto; Morishita,Takashi; Yoshimura,Masayo; Nonaka,Masani; Abe,Hiroshi; Inoue,Tooru; Nabeshima,Kazuki

doi:10.3892/ol.2018.9225

Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors

Authors:
- Hiromasa Kobayashi
- Makoto Hamasaki
- Takashi Morishita
- Masayo Yoshimura
- Masani Nonaka
- Hiroshi Abe
- Tooru Inoue
- Kazuki Nabeshima
View Affiliations

Affiliations: Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka 814‑0180, Japan, Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka 814‑0180, Japan
Published online on: July 27, 2018 https://doi.org/10.3892/ol.2018.9225
Pages: 4243-4252
Copyright: © Kobayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Brain metastases (BM) are common in patients with lung adenocarcinoma, and represent a significant cause of morbidity in the disease. A more comprehensive understanding of the clinicopathological characteristics that serve as prognostic factors for survival in patients with BM from lung adenocarcinoma may aid in informing treatment strategies for this patient population. In the present study, clinicopathological factors, including EGFR mutation status, were evaluated in 59 patients who were diagnosed with BM from lung adenocarcinoma, and underwent BM resection between January 1985 and December 2014 at Fukuoka University Hospital. The most frequent subtype of BM from lung adenocarcinoma was solid adenocarcinoma (57.6%), followed by papillary adenocarcinoma (22.0%) and acinar adenocarcinoma (18.6%). A total of 14 patients (23.7%) exhibited EGFR mutations, which were significantly associated with female sex (9/14, 64.3%), non‑smoker status (8/14, 57.1%), BM in the frontal lobes (9/14, 64.3%) and papillary adenocarcinoma (5/14, 35.7%). Statistical analysis revealed a significant association between non‑smoker status and BM in the frontal lobes, and more favorable disease prognosis. The results of the present study suggest that histological and genetic analysis of tissue from BM provides information useful for managing treatment of patients with resectable BM arising from lung adenocarcinoma.

View Figures

View References

1	Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB and Aquino SL: Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 1:205–210. 2006. View Article : Google Scholar : PubMed/NCBI
2	Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM and Johnson BE: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 16:5873–5882. 2010. View Article : Google Scholar : PubMed/NCBI
3	Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P and SAwaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol. 22:2865–2872. 2004. View Article : Google Scholar : PubMed/NCBI
4	Cox JD, Scott CB, Byhardt RW, Emami B, Russell AH, Fu KK, Parliament MB, Komaki R and Gasper LE: Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of radiation therapy oncology group (RTOG) trials. Int Radiat Oncol Biol Phys. 43:505–509. 1999. View Article : Google Scholar
5	Wang SY, Ye X, Ou W, Lin YB, Zhang BB and Yang H: Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer. 64:238–243;. 2009. View Article : Google Scholar : PubMed/NCBI
6	Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI
7	Sperduto PW, Berkey B, Gasper LE, Mehta M and Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: An anlysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 70:510–514. 2008. View Article : Google Scholar : PubMed/NCBI
8	Chang DB, Yang PC, Luh KT, Kuo SH, Hong RL and Lee LN: Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment. Chest. 101:1293–1297. 1992. View Article : Google Scholar : PubMed/NCBI
9	Kepka L, Cieslak E, Bujko K, Fijuth J and Wierzchowski M: Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: The RTOG RPA intra-classes analysis. Acta Oncol. 44:389–398. 2005. View Article : Google Scholar : PubMed/NCBI
10	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
11	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carbonplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
12	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oisumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
13	Shimato S, Mitsudomi T, Kosaka T, Yutabe Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D and Yoshida J: EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro Oncol. 8:137–144. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C and Lee JS: Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 65:351–354. 2009. View Article : Google Scholar : PubMed/NCBI
15	Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C and Lee JS: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
16	Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright GM, McLachlan SA, Dobrovic A and Russell PA: The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma. J Thorac Oncol. 9:654–663. 2014. View Article : Google Scholar : PubMed/NCBI
17	Amin MB, Tamboli P, Merchant SH, Ordonez NG, Ro J, Ayala AG and Ro JY: Micropapillary component in lung adenocarcinoma: A distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 26:358–364. 2002. View Article : Google Scholar : PubMed/NCBI
18	Travis WD BE, Burke AP, Marx A and Nicholson AG: WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart. 4th edition. IARC press; Lyon: 2015
19	Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824. 2007. View Article : Google Scholar : PubMed/NCBI
20	Mitsudori T, Kosaka T and Yatabe Y: Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 11:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
21	Shigematsu H, Lin L, Takahasi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yano M, Sasaki H, Kobayashi Y, Yukiue H, Haneda H, Suzuki E, Endo K, Kawano O, Hara M and Fujii Y: Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol. 1:413–416. 2006. View Article : Google Scholar : PubMed/NCBI
23	Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, et al: Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. Cancer. 118:4502–4511. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hendriks LE, Smit EF, Vosse BA, Mellema WW, Heideman DA, Bootsma GP, Westenend M, Pitz C, de Vries GJ, Houben R, et al: EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? Lung Cancer. 84:86–91. 2014. View Article : Google Scholar : PubMed/NCBI
25	Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS and Costa DB: Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 88:108–111. 2015. View Article : Google Scholar : PubMed/NCBI
26	Matsumoto S, Takahasi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E and Yokota J: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 119:1491–1494. 2006. View Article : Google Scholar : PubMed/NCBI
27	Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ and Sequist LV: EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 12:1193–1199. 2010. View Article : Google Scholar : PubMed/NCBI
28	Shin DY, Na II, Kim CH, Park S, Baek H and Yang SH: EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 9:195–199. 2014. View Article : Google Scholar : PubMed/NCBI
29	Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD and Wistuba II: HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 15:4829–4837. 2009. View Article : Google Scholar : PubMed/NCBI
30	Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al: International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
31	Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, Watanabe S, Takeuchi M, Furuta K, Asamura H and Tsuda H: The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alternations. Lung Cancer. 81:371–376. 2013. View Article : Google Scholar : PubMed/NCBI
32	Koga K, Hamasaki M, Kato F, Aoki M, Hayashi H, Iwasaki A, Kataoka H and Nabeshima K: Association of c-Met phosphorylation with micropapillary pattern and small cluster invasion in pT1-size lung adenocarcinoma. Lung Cancer. 82:413–419. 2013. View Article : Google Scholar : PubMed/NCBI
33	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicenter, open-label, randomized, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
34	Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, et al: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 31:895–902. 2013. View Article : Google Scholar : PubMed/NCBI
35	Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A and Cufer T: Brain metastases in lung adenocarcinoma: Impact of EGFR mutation status on incidence and survival. Radiol Oncol. 48:173–183. 2014. View Article : Google Scholar : PubMed/NCBI
36	Lee DW, Shin DY, Kim JW, Keam B, Kim TM, Kim HJ, Kim DW, Wu HG, Paek SH, Kim YW, et al: Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. Lung Cancer. 86:363–368. 2014. View Article : Google Scholar : PubMed/NCBI
37	Sekine A, Satoh H, Iwasawa T, Tamura K, Hayashihara K, Saito T, Kato T, Arai M, Okudela K, Ohashi K and Ogura T: Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: Influence of stable extracranial disease and erlotinib therapy. Med Oncol. 31:2282014. View Article : Google Scholar : PubMed/NCBI
38	Tanriverdi T, Kemerdere R, Baran O, Sayyahmelli S, Ozlen F, Isler C, Uzan M and Ozyurt E: Long-term surgical and seizure outcomes of frontal low-grade gliomas. Int J Surg. 33:60–64. 2016. View Article : Google Scholar : PubMed/NCBI